188 related articles for article (PubMed ID: 30510495)
1. Combined Volumetric and Density Analyses of Contrast-Enhanced CT Imaging to Assess Drug Therapy Response in Gastroenteropancreatic Neuroendocrine Diffuse Liver Metastasis.
Wang Y; Huang K; Chen J; Luo Y; Zhang Y; Jia Y; Xu L; Chen M; Huang B; Ni D; Li ZP; Feng ST
Contrast Media Mol Imaging; 2018; 2018():6037273. PubMed ID: 30510495
[TBL] [Abstract][Full Text] [Related]
2. Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
Luo Y; Chen J; Huang K; Lin Y; Chen M; Xu L; Li ZP; Feng ST
BMC Cancer; 2017 Feb; 17(1):154. PubMed ID: 28231773
[TBL] [Abstract][Full Text] [Related]
3. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
4. Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?
Naswa N; Sharma P; Gupta SK; Karunanithi S; Reddy RM; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
Clin Nucl Med; 2014 Jan; 39(1):e27-34. PubMed ID: 24217539
[TBL] [Abstract][Full Text] [Related]
5. CT evaluation of response in advanced gastroenteropancreatic neuroendocrine tumors treated with long-acting-repeatable octreotide: what is the optimal size variation threshold?
Luo Y; Chen J; Shen B; Wang M; Cai H; Xu L; Chen L; Chen M; Li ZP; Feng ST
Eur Radiol; 2018 Dec; 28(12):5250-5257. PubMed ID: 29876704
[TBL] [Abstract][Full Text] [Related]
6. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Contrast-Enhanced CT + CT Enterography and 68Ga-DOTANOC PET/CT in Gastroenteropancreatic Neuroendocrine Tumors.
Sharma A; Das CJ; Makharia GK; Arora G; Kumar R
Clin Nucl Med; 2020 Nov; 45(11):848-853. PubMed ID: 32657875
[TBL] [Abstract][Full Text] [Related]
8. Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy.
Luboldt W; Hartmann H; Wiedemann B; Zöphel K; Luboldt HJ
Mol Imaging; 2010 Dec; 9(6):351-8. PubMed ID: 21084031
[TBL] [Abstract][Full Text] [Related]
9. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors?
Has Simsek D; Kuyumcu S; Turkmen C; Sanlı Y; Aykan F; Unal S; Adalet I
J Nucl Med; 2014 Nov; 55(11):1811-7. PubMed ID: 25315243
[TBL] [Abstract][Full Text] [Related]
10. Sensitivity Comparison of
Nicolas GP; Schreiter N; Kaul F; Uiters J; Bouterfa H; Kaufmann J; Erlanger TE; Cathomas R; Christ E; Fani M; Wild D
J Nucl Med; 2018 Jun; 59(6):915-921. PubMed ID: 29191855
[TBL] [Abstract][Full Text] [Related]
11. Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Baumann T; Rottenburger C; Nicolas G; Wild D
Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):45-57. PubMed ID: 26971843
[TBL] [Abstract][Full Text] [Related]
12. Diffuse Bone Metastases in Pancreatic Neuroendocrine Tumor Shown on Octreoscan.
Adkins J; Lu Y
Clin Nucl Med; 2019 Mar; 44(3):257-258. PubMed ID: 30624276
[TBL] [Abstract][Full Text] [Related]
13. High prognostic value of 18F-FDG PET for metastatic gastroenteropancreatic neuroendocrine tumors: a long-term evaluation.
Bahri H; Laurence L; Edeline J; Leghzali H; Devillers A; Raoul JL; Cuggia M; Mesbah H; Clement B; Boucher E; Garin E
J Nucl Med; 2014 Nov; 55(11):1786-90. PubMed ID: 25286923
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
15. Is There an Additional Value of Using Somatostatin Receptor Subtype 2a Immunohistochemistry Compared to Somatostatin Receptor Scintigraphy Uptake in Predicting Gastroenteropancreatic Neuroendocrine Tumor Response?
van Adrichem RC; Kamp K; van Deurzen CH; Biermann K; Feelders RA; Franssen GJ; Kwekkeboom DJ; Hofland LJ; de Herder WW
Neuroendocrinology; 2016; 103(5):560-6. PubMed ID: 26536001
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor.
Yoo C; Cho H; Song MJ; Hong SM; Kim KP; Chang HM; Chae H; Kim TW; Hong YS; Ryu MH; Kang YK; Kim SC; Ryoo BY
Cancer Chemother Pharmacol; 2017 Jan; 79(1):139-146. PubMed ID: 27942928
[TBL] [Abstract][Full Text] [Related]
17. The multidisciplinary team for gastroenteropancreatic neuroendocrine tumours: the radiologist's challenge.
Granata V; Fusco R; Setola SV; Castelguidone ELD; Camera L; Tafuto S; Avallone A; Belli A; Incollingo P; Palaia R; Izzo F; Petrillo A
Radiol Oncol; 2019 Oct; 53(4):373-387. PubMed ID: 31652122
[TBL] [Abstract][Full Text] [Related]
18. Clinical Usefulness of Somatostatin Receptor Scintigraphy in Japanese Patients with Gastroenteropancreatic Neuroendocrine Tumors.
Hasegawa S; Kobayashi N; Tokuhisa M; Goto A; Takano S; Takada Y; Kaneta T; Mori R; Matsuyama R; Endo I; Yamanaka S; Nakajima A; Inoue T; Ichikawa Y
Digestion; 2017; 96(1):13-20. PubMed ID: 28609761
[TBL] [Abstract][Full Text] [Related]
19. Gastroenteropancreatic neuroendocrine tumors: impact of consistent contrast agent selection on radiologists' confidence in hepatic lesion assessment on restaging MRIs.
Balthazar P; Shinagare AB; Tirumani SH; Jagannathan JP; Ramaiya NH; Khorasani R
Abdom Radiol (NY); 2018 Jun; 43(6):1386-1392. PubMed ID: 28840281
[TBL] [Abstract][Full Text] [Related]
20. [CT and MRI findings of primary hepatic neuroendocrine neoplasm].
Li JK; Wang M; Yuan J; Song ZG
Zhonghua Zhong Liu Za Zhi; 2017 Aug; 39(8):600-606. PubMed ID: 28835083
[No Abstract] [Full Text] [Related]
[Next] [New Search]
